The disposition of intraperitoneal bleomycin, melphalan, and vinblastine in cancer patients.

David S Alberts, H. S. Chen, S. Y. Chang, Y. M. Peng

Research output: Contribution to journalArticle

13 Citations (Scopus)

Abstract

We have studied the disposition of bleomycin, melphalan, or vinblastine after intraperitoneal (IP) instillation in 14 cancer patients. Although IP bleomycin had a somewhat longer terminal-phase plasma half-life than after intravenous (IV) administration (5.5 vs 4.0 h, respectively), its systemic absorption averaged only 44%-52% of the administered dose. IP melphalan's mean terminal-phase half-life of 1.3 h was similar to that seen after IV drug administration. Melphalan's systemic absorption form the IP space averaged only 39% of the administered dose. In contrast, vinblastine plasma levels remained elevated for longer than 24 h after IP instillation. Its use was associated with life-threatening adynamic ileus in two patients. Bleomycin's and melphalan's reduced systemic availability after IP dosing suggests that their dose could be increased safely by a factor of two over their standard IV doses.

Original languageEnglish (US)
Pages (from-to)293-299
Number of pages7
JournalRecent results in cancer research. Fortschritte der Krebsforschung. Progrès dans les recherches sur le cancer
Volume74
StatePublished - 1980
Externally publishedYes

Fingerprint

Melphalan
Vinblastine
Bleomycin
Intravenous Administration
Half-Life
Neoplasms
Ileus
Pharmaceutical Preparations
Physiological Absorption

ASJC Scopus subject areas

  • Medicine(all)

Cite this

@article{5f7d2006fe8546fe9e3ba3f42aa4d9bd,
title = "The disposition of intraperitoneal bleomycin, melphalan, and vinblastine in cancer patients.",
abstract = "We have studied the disposition of bleomycin, melphalan, or vinblastine after intraperitoneal (IP) instillation in 14 cancer patients. Although IP bleomycin had a somewhat longer terminal-phase plasma half-life than after intravenous (IV) administration (5.5 vs 4.0 h, respectively), its systemic absorption averaged only 44{\%}-52{\%} of the administered dose. IP melphalan's mean terminal-phase half-life of 1.3 h was similar to that seen after IV drug administration. Melphalan's systemic absorption form the IP space averaged only 39{\%} of the administered dose. In contrast, vinblastine plasma levels remained elevated for longer than 24 h after IP instillation. Its use was associated with life-threatening adynamic ileus in two patients. Bleomycin's and melphalan's reduced systemic availability after IP dosing suggests that their dose could be increased safely by a factor of two over their standard IV doses.",
author = "Alberts, {David S} and Chen, {H. S.} and Chang, {S. Y.} and Peng, {Y. M.}",
year = "1980",
language = "English (US)",
volume = "74",
pages = "293--299",
journal = "Recent Results in Cancer Research",
issn = "0080-0015",
publisher = "Springer New York",

}

TY - JOUR

T1 - The disposition of intraperitoneal bleomycin, melphalan, and vinblastine in cancer patients.

AU - Alberts, David S

AU - Chen, H. S.

AU - Chang, S. Y.

AU - Peng, Y. M.

PY - 1980

Y1 - 1980

N2 - We have studied the disposition of bleomycin, melphalan, or vinblastine after intraperitoneal (IP) instillation in 14 cancer patients. Although IP bleomycin had a somewhat longer terminal-phase plasma half-life than after intravenous (IV) administration (5.5 vs 4.0 h, respectively), its systemic absorption averaged only 44%-52% of the administered dose. IP melphalan's mean terminal-phase half-life of 1.3 h was similar to that seen after IV drug administration. Melphalan's systemic absorption form the IP space averaged only 39% of the administered dose. In contrast, vinblastine plasma levels remained elevated for longer than 24 h after IP instillation. Its use was associated with life-threatening adynamic ileus in two patients. Bleomycin's and melphalan's reduced systemic availability after IP dosing suggests that their dose could be increased safely by a factor of two over their standard IV doses.

AB - We have studied the disposition of bleomycin, melphalan, or vinblastine after intraperitoneal (IP) instillation in 14 cancer patients. Although IP bleomycin had a somewhat longer terminal-phase plasma half-life than after intravenous (IV) administration (5.5 vs 4.0 h, respectively), its systemic absorption averaged only 44%-52% of the administered dose. IP melphalan's mean terminal-phase half-life of 1.3 h was similar to that seen after IV drug administration. Melphalan's systemic absorption form the IP space averaged only 39% of the administered dose. In contrast, vinblastine plasma levels remained elevated for longer than 24 h after IP instillation. Its use was associated with life-threatening adynamic ileus in two patients. Bleomycin's and melphalan's reduced systemic availability after IP dosing suggests that their dose could be increased safely by a factor of two over their standard IV doses.

UR - http://www.scopus.com/inward/record.url?scp=0019280928&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0019280928&partnerID=8YFLogxK

M3 - Article

C2 - 6160601

AN - SCOPUS:0019280928

VL - 74

SP - 293

EP - 299

JO - Recent Results in Cancer Research

JF - Recent Results in Cancer Research

SN - 0080-0015

ER -